article thumbnail

Preventing fungal contamination in pharmaceuticals

European Pharmaceutical Review

Additionally, this can be caused by “poor handling, repackaging, and nonadherence to good manufacturing practices [GMP] during dispensing and packaging have resulted in the microbiological contamination of non-sterile pharmaceutical products.” Ahmed et al.

article thumbnail

Digital investment promises to accelerate the use of wearable sensor data in clinical trials

pharmaphorum

Garabedian and his team plan to support VivoSense, not just with their funding package but with their industry network and connectivity. “We In 2010, when we founded VivoSense, we developed a software platform for analysis of wearable sensor data and electronic patient-recorded outcomes (PRO) and patient diary information.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Are microtaggants the key to making medicines smarter?

pharmaphorum

Pharmaceutical companies are accountable for ensuring that their medicine is safe when it comes into the hands of patients. Many countries have introduced serialisation legislation which requires product identifiers to be affixed to each package to provide traceability throughout the distribution supply chain. Reduce wastage.

article thumbnail

Why Are FDA Inspections So Ineffective and Disappointing?

The People's Pharmacy

The same was true of another of the company’s products, Delsam Pharma Artificial Eye Ointment , which the company voluntarily recalled shortly after. “The FDA said Global Pharma failed to use adequate, tamper-evident packaging and distributed the drugs without proper preservatives.”

FDA 72
article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Pharmaceutical companies – and the FDA – are embracing FDCs. Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. The potential to extend the patent life and market exclusivity of a company’s APIs is a potent financial incentive. The numbers tell the story.

article thumbnail

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

Roots Analysis

The support from venture capitalists and big pharmaceutical companies will continue to drive the development of circular RNA therapeutics and RNA therapeutics market growth over the forecast period. Considering the potential of these therapies, several industry stakeholders are actively engaging in the development of such therapeutics.

article thumbnail

What to Keep in Your Integrative Medicine Cabinet

The Thyroid Pharmacist

Follow package instructions. Follow package directions for each supplement. Sleep issues: I like to recommend Epsom salt baths, which contain magnesium that is absorbed through the skin (1 cup of salts per tub – follow package instructions, and don’t overdo it!), Pharmaceuticals (Basel). Published 2010 Jan 19.